Alnylam Pharmaceuticals reported $1.46B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Arrowhead Research USD 450.82M 375.59M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.3B 160M Jun/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Takeda JPY 1.19T 32.9B Sep/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026